Joseph Jimenez - Novartis CEO, Member of the Executive Committee
| NVSEF Stock | USD 93.64 0.46 0.49% |
CEO
Mr. Joseph S. Jimenez was Chief Executive Officer and Member of the Executive Committee of Novartis Inc. from February 1, 2010 to January 31, 2018. Mr. Jimenez previously held the position of Division Head, Novartis Pharmaceuticals. He joined Novartis in 2007 as Division Head, Novartis Consumer Health. Before that, from 1998 to 2006, he served as president and CEO of the North American and European businesses for the H.J. Heinz Company. He also served on the board of directors of ColgatePalmolive Co. from 2009 to 2015, and of AstraZeneca PLC from 2002 to 2007 since 2010.
| Age | 58 |
| Tenure | 14 years |
| Professional Marks | MBA |
| Phone | 41 61 324 1111 |
| Web | https://www.novartis.com |
Novartis Management Efficiency
The company has return on total asset (ROA) of 0.0645 % which means that it generated a profit of $0.0645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1093 %, meaning that it generated $0.1093 on every $100 dollars invested by stockholders. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | CEO Age | ||
| Nacho Abia | Grifols SA ADR | 56 | |
| Osamu Nagayama | Roche Holding Ltd | 69 | |
| PerOlof Attinger | Roche Holding Ltd | 58 | |
| Javier Ribes | Grifols SA ADR | N/A | |
| Albert Roura | Grifols SA ADR | N/A | |
| William Anderson | Roche Holding Ltd | 57 | |
| Severin Schwan | Roche Holding Ltd | 56 | |
| Michael Heuer | Roche Holding Ltd | 64 | |
| Victor Deu | Grifols SA ADR | N/A | |
Management Performance
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 |
Novartis AG Leadership Team
Elected by the shareholders, the Novartis' board of directors comprises two types of representatives: Novartis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novartis. The board's role is to monitor Novartis' management team and ensure that shareholders' interests are well served. Novartis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novartis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ton Buechner, Non-Executive Independent Director | ||
| Robert PharmD, Chief Officer | ||
| Verena Briner, Non-Executive Independent Member of the Board | ||
| Karen Hale, Chief Officer | ||
| Chris Ilsley, President CEO | ||
| Steven Baert, Head of HR | ||
| Richard Saynor, Chief Sandoz | ||
| Richard Francis, Member of the Executive Committee and Division Head, Sandoz | ||
| Daniel Vasella, Honorary Chairman of the Board | ||
| Pierre Landolt, Member of the Board of Directors | ||
| Elizabeth Doherty, Non-Executive Independent Director | ||
| Erwin Vanhaecke, Head Novartis Group Quality | ||
| Elizabeth Barrett, CEO, Novartis Oncology | ||
| Mark Fishman, Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR) | ||
| Charlotte PamerWieser, Corporate Secretary | ||
| Shannon Klinger, Chief Risk and Compliance Officer, Group General Counsel | ||
| Samir Shah, Global Head Investor Relations | ||
| David Epstein, Member of the Executive Committee, Division Head, Pharmaceuticals | ||
| Srikant Datar, Member of the Board of Directors | ||
| MarieFrance Tschudin, Pres Officer | ||
| Samir MD, Global Relations | ||
| Francesco Balestrieri, CEO of Sandoz, Member of the Executive Committee | ||
| Steffen Lang, Global Head of Novartis Technical Operations, Member of the Executive Committee | ||
| Paul Penepent, Head Accounting | ||
| Joerg Reinhardt, Chairman of the Board | ||
| Paul Hudson, CEO of Novartis Pharmaceuticals, Member of the Executive Committee | ||
| Brian McNamara, Member of the Management Board, Division Head, Novartis OTC | ||
| Michele Galen, Head Communications | ||
| Charles Sawyers, Non-Executive Independent Member of the Board | ||
| John Tsai, Head of Global Drug Development and Chief Medical Office, Member of the Executive Committee | ||
| Dimitri Azar, Member of the Board of Directors | ||
| Frans Houten, Non-Executive Independent Director | ||
| Nancy Andrews, Non-Executive Independent Director | ||
| Susanne Schaffert, CEO Novartis Oncology, Member of the Executive Committee | ||
| Enrico Vanni, Member of the Board of Directors | ||
| Bertrand Bodson, Chief Digital Officer, Member of the Executive Committee | ||
| Robert Weltevreden, Head of Novartis Business Services (NBS), Member of the Executive Committee | ||
| Andre Wyss, Member of the Executive Committee, Novartis Business Services and Country President for Switzerland | ||
| Bruno Strigini, CEO of Novartis Oncology, Member of the Executive Committee | ||
| Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee | ||
| Alex Krauer, Honorary Chairman of the Board | ||
| Michael Ball, CEO of Alcon, Member of the Executive Committee | ||
| Jeffrey George, Member of the Executive Committee and Division Head, Sandoz | ||
| Peter Kornicker, Chief Compliance Officer | ||
| Andreas Planta, Member of the Board of Directors | ||
| Joseph Jimenez, CEO, Member of the Executive Committee | ||
| Ulrich Lehner, Vice Chairman of the Board of Directors, Non-Executive Director | ||
| William Winters, Non-Executive Independent Member of the Board | ||
| Ann Fudge, Member of the Board of Directors | ||
| George Gunn, Member of the Executive Committee, Division Head, Novartis Animal Health of Head, Corporate Responsibility | ||
| Paul Arkel, Head of Corporate Strategy and External Affairs | ||
| James Bradner, President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee | ||
| Klaus Moosmayer, Chief Ethics Risk and Compliance Officer, Member of the Executive Committee | ||
| Felix Ehrat, General Counsel and General Counsel of Novartis International Ag | ||
| Harry Kirsch, Chief Officer | ||
| Andrin Oswald, Member of the Executive Committee, Division Head, Vaccines and Diagnostics |
Novartis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novartis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 207.39 B | |||
| Shares Outstanding | 2.12 B | |||
| Shares Owned By Insiders | 3.74 % | |||
| Shares Owned By Institutions | 33.74 % | |||
| Price To Earning | 25.00 X | |||
| Price To Book | 3.22 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novartis in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novartis' short interest history, or implied volatility extrapolated from Novartis options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the Novartis AG information on this page should be used as a complementary analysis to other Novartis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Complementary Tools for Novartis Pink Sheet analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |